RxDoctor Payments Data

Swapna Omraju, MD

Internal Medicine · Mt Pleasant, SCNPI 1891931713

Payments from drug & device makers

$9,591in general payments, 2019–2025

Across 532 payments — averaging $18.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Pfizer$1K
  • AbbVie$981
  • Lilly USA, LLC$865
  • AstraZeneca$760
  • Amgen$610
  • plus $4K from 41 others

What the payments were for

  • Food & beverage$9,591100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,591 in reported general payments places this provider in the 90th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$240,885
Medicare patients
554
Services billed
3,180

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin91$100,757
EliquisApixaban78$81,430
FarxigaDapagliflozin Propanediol68$78,570
JanuviaSitagliptin Phosphate52$63,538
OzempicSemaglutide39$45,488
TrulicityDulaglutide27$32,157
MounjaroTirzepatide26$29,928
LinzessLinaclotide25$23,353
MyrbetriqMirabegron17$14,669
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$14,116
Rosuvastatin Calcium495$10,005
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$8,530
TrintellixVortioxetine Hydrobromide12$5,914
Atorvastatin Calcium359$4,677
Ezetimibe78$3,870

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Stiolto Respimat$600$109,287102 claims
PfizerEliquis$1,032$81,43078 claims
AstraZenecaFarxiga$760$78,57068 claims
MerckJanuvia$71$63,53852 claims
Lilly USA, LLCTrulicity, Mounjaro$865$62,08653 claims
Novo NordiskOzempic$1,238$45,48839 claims
AbbVieLinzess, Synthroid$981$25,90160 claims
Astellas Pharma US IncMyrbetriq$164$14,66917 claims
GSKTrelegy Ellipta$283$14,11615 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$195$5,91412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Mt Pleasant

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →